GlobalData analysts have tipped the global market for genomic therapies to balloon to almost $90 billion by 2030, driven by ...

Concerns are being raised over plans to build hundreds of new houses and flats on land in Horsham that is feared could be ...

The Novartis oncology strategy focuses on people living with cancer and those who care for them, from loved ones to clinical care teams, including their providers. For the past 30+ years, the aim has ...

Roche is among several drugmakers to announce large-scale U.S. investments in response to Trump's push to onshore ...

U.S. President Donald Trump's executive order on drug pricing threatens Roche's planned $50 billion investment in the United ...

Incyte said it agreed to pay Novartis $280 million to settle the disputed royalties on U.S. sales of blood-cancer treatment Jakafi through Dec. 31. The parties also agreed to reduce by 50% the royalty ...

The move comes as GSK faces pressure to replenish its pipeline, with some of its top-selling drugs nearing the end of their ...

Risk for the autoimmune hair disorder was reduced by nearly 75% in patients on these treatments for psoriasis, finds a ...

Revisions to classification criteria ‘will ensure homogeneous trial populations’ with data-driven scoring, a standardized MRI ...

Analysts are still crunching the numbers on the impact of President Donald Trump's executive order from Monday on drug pricing. HSBC analyst Rajesh Kumar says a 20% price cut in government channels ...

Swiss drugmaker Novartis will keep making medicines for malaria and leprosy, even if it does not get orders as normal amid ...

Global pharmaceutical shares are slumping Monday after President Donald Trump said he is looking to slash the price of ...